Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
Mallinckrodt
McKesson
Harvard Business School

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,901,666

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,901,666
Title:Nanoparticles for protein drug delivery
Abstract: The invention discloses a pharmaceutical composition for treating a subject comprising two or more bioactive nanoparticles, thus treating the subject by co-administering the bioactive nanoparticles to the subject, wherein a first and a second bioactive nanoparticles comprise a shell portion that is dominated by positively charged chitosan, a core portion that contains negatively charged substrate, and at least a first bioactive agent in the first nanoparticle and a second bioactive agent in the second nanoparticle.
Inventor(s): Sung; Hsing-Wen (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee: GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW)
Application Number:12/455,339
Patent Claims:1. A pharmaceutical composition for treating a subject comprising two or more bioactive nanoparticles, thus treating the subject by co-administering said two or more bioactive nanoparticles to said subject, wherein a first bioactive nanoparticle comprises a shell portion that is dominated by a first positively charged chitosan, a core portion that consists of a first negatively charged substrate, the first positively charged chitosan, and at least a zero-charge first compound, and wherein a second bioactive nanoparticle comprises a shell portion that is dominated by a second positively charged chitosan, a core portion that contains a second negatively charged substrate, the second positively charged chitosan, and at least a second compound.

2. The pharmaceutical composition of claim 1, wherein the first and second nanoparticles are loaded in capsules.

3. The pharmaceutical composition of claim 2, wherein said capsules are treated with an enteric coating.

4. The pharmaceutical composition of claim 2, wherein said capsules further comprise at least a solubilizer or pharmacopoeial excipients.

5. The pharmaceutical composition of claim 2, wherein said capsules further comprise a permeation enhancer.

6. The pharmaceutical composition of claim 5, wherein said permeation enhancer is selected from the group consisting of Ca.sup.2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives.

7. The pharmaceutical composition of claim 1, wherein the first nanoparticle is loaded in a first capsule and the second nanoparticle is loaded in a second capsule for co-administration to said subject.

8. The pharmaceutical composition of claim 7, wherein said first capsule or said second capsule is treated with an enteric coating.

9. The pharmaceutical composition of claim 7, wherein said first capsule or said second capsule further comprises at least a solubilizer or pharmacopoeial excipients.

10. The pharmaceutical composition of claim 7, wherein said first capsule or said second capsule further comprises a permeation enhancer.

11. The pharmaceutical composition of claim 10, wherein said permeation enhancer is selected from the group consisting of Ca.sup.2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives.

12. The pharmaceutical composition of claim 1, wherein the first or second chitosan comprises N-trimethyl chitosan, EDTA-chitosan, or chitosan derivatives.

13. The pharmaceutical composition of claim 1, wherein said first and second nanoparticles are loaded in tablets or pills.

14. The pharmaceutical composition of claim 1, wherein said first and second nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form.

15. The pharmaceutical composition of claim 1, wherein said second compound further comprises magnesium sulfate or TPP.

16. The pharmaceutical composition of claim 1, wherein the second compound comprises at least one non-insulin anti-diabetic drug.

17. The pharmaceutical composition of claim 16, wherein said non-insulin anti-diabetic drug is selected from the group consisting of insulin sensitizers, insulin secretagogues, GLP-1 analogs, and DPP-4 inhibitors.

18. The pharmaceutical composition of claim 16, wherein said non-insulin anti-diabetic drug comprises liraglutide, exenatide, albiglutide, or taspoglutide.

19. The pharmaceutical composition of claim 16, wherein said non-insulin anti-diabetic drug is selected from the group consisting of alpha-glucosidase inhibitors, amylin analog, sodium-glucose co-transporter type 2 (SGLT2) inhibitors, benfluorex, and tolrestat.

20. The pharmaceutical composition of claim 1, wherein the first or second compound is insulin or an insulin analog.

Details for Patent 7,901,666

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Llc TANZEUM albiglutide INJECTABLE;INJECTION 125431 001 2014-04-15   Start Trial GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW) 2025-01-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Dow
Baxter
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.